Voyager Therapeutics (VYGR) Upgraded at BidaskClub

Voyager Therapeutics (NASDAQ:VYGR) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a report released on Friday.

VYGR has been the subject of a number of other research reports. Chardan Capital reissued a “hold” rating and issued a $17.00 target price on shares of Voyager Therapeutics in a report on Tuesday, October 31st. Canaccord Genuity initiated coverage on shares of Voyager Therapeutics in a report on Friday, October 27th. They issued a “buy” rating and a $35.00 target price for the company. ValuEngine raised shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. Raymond James Financial initiated coverage on shares of Voyager Therapeutics in a report on Thursday, October 12th. They issued an “outperform” rating and a $35.00 target price for the company. Finally, BTIG Research initiated coverage on shares of Voyager Therapeutics in a report on Tuesday, December 19th. They issued a “buy” rating and a $32.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and twelve have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $26.90.

Voyager Therapeutics (NASDAQ:VYGR) traded down $0.05 during mid-day trading on Friday, hitting $17.86. 335,579 shares of the stock were exchanged, compared to its average volume of 355,925. The company has a market capitalization of $474.04 and a PE ratio of -6.29. Voyager Therapeutics has a 52-week low of $8.10 and a 52-week high of $25.99.

In other news, insider Bernard Ravina sold 5,490 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $13.26, for a total value of $72,797.40. Following the completion of the transaction, the insider now owns 16,473 shares of the company’s stock, valued at $218,431.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 21,960 shares of company stock valued at $370,850 in the last ninety days. 8.00% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in the company. Schwab Charles Investment Management Inc. increased its stake in shares of Voyager Therapeutics by 0.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 29,035 shares of the company’s stock valued at $261,000 after buying an additional 114 shares during the period. Goldman Sachs Group Inc. increased its position in Voyager Therapeutics by 8.9% during the 2nd quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock valued at $153,000 after purchasing an additional 1,399 shares during the period. California State Teachers Retirement System increased its position in Voyager Therapeutics by 8.4% during the 2nd quarter. California State Teachers Retirement System now owns 25,811 shares of the company’s stock valued at $231,000 after purchasing an additional 2,000 shares during the period. TIAA CREF Investment Management LLC increased its position in Voyager Therapeutics by 11.8% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 37,295 shares of the company’s stock valued at $334,000 after purchasing an additional 3,939 shares during the period. Finally, Rhumbline Advisers increased its position in Voyager Therapeutics by 34.7% during the 2nd quarter. Rhumbline Advisers now owns 16,091 shares of the company’s stock valued at $144,000 after purchasing an additional 4,144 shares during the period. 35.97% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/05/voyager-therapeutics-vygr-upgraded-at-bidaskclub.html.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply